Table 4.
Point estimates of the incremental cost-effectiveness ratios (ICER) for PoC testing per patient maintained in the target range* compared with laboratory testing
| Test | Treatment Group | Costs per patient ($) | Effects per patient * | ICER ($) |
|---|---|---|---|---|
| INR | Intervention (PoCT) | 3,298 | 0.5701 | |
| Control (Laboratory) | 3,150 | 0.6147 | ||
| Difference | 148 | -0.0446 | Dominated | |
| HbA1c | Intervention (PoCT) | 3,676 | 0.6548 | |
| Control (Laboratory) | 3672 | 0.5618 | ||
| Difference | 4 | 0.0930 | $40 | |
| ACR | Intervention (PoCT) | 1,727 | 0.7739 | |
| Control (Laboratory) | 1,954 | 0.7418 | ||
| Difference | -228 | 0.0321 | Dominant | |
| Lipids | Intervention (PoCT) | 2,732 | 0.1592 | |
| Control (Laboratory) | 2,202 | 0.1066 | ||
| Difference | 530 | 0.0526 | $10,082 | |
*Effect is the proportion of patients in target range as determined at the end of the Trial (18 months mean observation time)